Table 1.

Tumor characteristics of the 20 oligometastatic lesions included for analysis

Site	Histology	GTV (cm3)	PTV (cm3)	PTV-opt (cm3)	PTV-opt /PTV	Constraining OAR	Max dose constraint (Gy)
Lung	Pancreas adenocarcinoma	1.51	6.31	3.39	0.54	Bronchus	20.2
Lung	Lung adenocarcinoma	13.11	26.40	26.10	0.99	Stomach	12.4
Lung	Lung adenocarcinoma	8.07	25.43	22.00	0.87	Esophagus	15.4
Lung	Esophagus adenocarcinoma	10.85	24.59	17.75	0.72	Rib	22∗
Lung	Cholangiocarcinoma	3.35	13.57	10.02	0.74	Rib	22∗
Lung	Breast invasive ductal carcinoma	3.77	16.23	16.23	1.00	Rib	22∗
Lung	Leiomyosarcoma	1.15	7.77	7.77	1.00	NA	NA
Lung	Melanoma	0.79	7.16	7.16	1.00	NA	NA
Lung	Renal cell carcinoma	4.18	12.55	12.55	1.00	NA	NA
Lung	Colorectal adenocarcinoma	1.02	4.02	4.02	1.00	NA	NA
Kidney	Colorectal adenocarcinoma	8.57	19.63	16.00	0.82	Small bowel	15.4
Kidney	Esophagus adenocarcinoma	6.82	17.46	14.95	0.86	Small bowel	15.4
Adrenal	Lung adenocarcinoma	49.27	87.22	79.74	0.91	Stomach	12.4
Portal lymph node	Hepatocellular carcinoma	65.66	112.06	108.70	0.97	Duodenum	12.4
Portacaval lymph node	Gall bladder adenocarcinoma	7.17	60.74	53.56	0.88	Stomach	12.4
Gastrohepatic lymph node	Esophagus adenocarcinoma	12.50	21.61	16.57	0.77	Stomach	12.4
Liver	Breast invasive ductal carcinoma	1.64	9.51	8.87	0.93	Stomach	12.4
Liver	Gall bladder adenocarcinoma	84.18	144.98	133.62	0.92	Duodenum	12.4
Liver	Lung adenocarcinoma	5.61	13.78	9.60	0.70	Colon	18.4
Liver	Pancreas adenocarcinoma	33.34	58.12	49.79	0.86	Colon	18.4
Mean (range)		16.12 (0.79-84.18)	34.46 (4.02-144.98)	30.92 (3.39-133.62)	0.87 (0.54-1.00)

Each lesion with a corresponding dose-limiting OAR and the maximum dose constraint of that OAR is indicated. PTVopt created by a Boolean subtraction of the 3 to 5 mm expansion around luminal organs from the PTV.

Abbreviations: GTV = gross tumor volume; NA = not applicable; OAR = organ at risk; PTV = planning target volume.

^∗D1cc (minimum dose to the 1 cm³ receiving the highest dose).